Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
TERIPARATIDE
ELI LILLY CANADA INC
H05AA02
TERIPARATIDE
250MCG
SOLUTION
TERIPARATIDE 250MCG
SUBCUTANEOUS
3ML PEN
Prescription
PARATHYROID AGENTS
Active ingredient group (AIG) number: 0150152001; AHFS:
APPROVED
2004-06-03
_ _ _ _ _Page 1 of 50 _ PRODUCT MONOGRAPH Pr FORTEO ® [teriparatide (rDNA origin) injection] Sterile Solution for Subcutaneous Injection 250 mcg/mL in 3 mL prefilled pen 250 mcg/mL in 2.4 mL prefilled pen Bone Formation Agent Eli Lilly Canada Inc. Exchange Tower 130 King Street West, Suite 900 P.O. Box 73 Toronto, Ontario M5X 1B1 1-888-545-5972 www.lilly.ca Date of Approval February 9, 2010 Revision Date August 12, 2021 Submission Control No: 242741 _ _ _ _ _Page 2 of 50 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .......................................................3 SUMMARY PRODUCT INFORMATION ..................................................................... 3 DESCRIPTION ............................................................................................................. 3 INDICATIONS AND CLINICAL USE .......................................................................... 3 CONTRAINDICATIONS .............................................................................................. 4 WARNINGS AND PRECAUTIONS .............................................................................. 5 ADVERSE REACTIONS............................................................................................... 7 DRUG INTERACTIONS ............................................................................................. 11 DOSAGE AND ADMINISTRATION .......................................................................... 12 OVERDOSAGE .......................................................................................................... 12 ACTION AND CLINICAL PHARMACOLOGY.......................................................... 13 STORAGE AND STABILITY ..................................................................................... 17 INSTRUCTIONS FOR PEN USE................................................................................. 17 DOSAGE FORMS, COMPOSITION AND PACKAGING ........................................... 17 PART II: SCIENTIFIC INFORMATION ............... Կարդացեք ամբողջական փաստաթուղթը